PF-Atlas › Clinical Trials › NCT05290441
Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia
None involvement · Not specified
Registry ID
NCT05290441
Phase
Not specified
Status
Completed
Drug / intervention
None involvement
Sponsor
Bursa Yuksek Ihtisas Training and Research Hospital
Start
2021-08-15
Enrollment
65
Locations
2
About this trial
The aim of this study is to examine the relationship between the severity of fibrosis in the lung tissue and EGFR positivity in patients who died due to covid-19 pneumonia, with the demographic characteristics, comorbidities, biochemistry values, treatments they received, and radiological appearances. Transthoracic tru-cut biopsy will be performed on patients who have died in the intensive care unit with the diagnosis of Covid 19 pneumonia. EGFR positivity will be evaluated in the material taken. The relationship between the severity of fibrosis and the demographic data of the patients, the drugs used and their radiological appearances will be analyzed statistically.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05290441 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.